Advertisement
New Zealand markets closed
  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     
  • NZD/USD

    0.5948
    -0.0001 (-0.02%)
     
  • NZD/EUR

    0.5555
    +0.0015 (+0.27%)
     
  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     
  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     
  • OIL

    83.74
    +0.17 (+0.20%)
     
  • GOLD

    2,350.80
    +8.30 (+0.35%)
     
  • NASDAQ

    17,717.57
    +287.07 (+1.65%)
     
  • FTSE

    8,139.83
    +60.97 (+0.75%)
     
  • Dow Jones

    38,285.50
    +199.70 (+0.52%)
     
  • DAX

    18,161.01
    +243.73 (+1.36%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • NZD/JPY

    93.7960
    +1.3000 (+1.41%)
     

This Healthcare Giant Expects Revenue to Crash More Than 30% This Year

This Healthcare Giant Expects Revenue to Crash More Than 30% This Year

Last year was a stellar one for Pfizer (NYSE: PFE). In January, Pfizer announced not only its latest earnings results but also a forecast for 2023, which tells investors what they already knew was inevitable: a sharp decline in sales is coming. A decline in revenue isn't a shock given that concerns surrounding COVID appear to be fading, but the reason for the soft numbers isn't entirely due to demand.